Pe­ter Thiel jumps aboard Al­loy's lat­est $75M round, adding some heft to the an­ti­body dis­cov­ery out­fit's nascent plat­form

In the world of ven­ture cap­i­tal, names mat­ter — and few names are big­ger than Sil­i­con Val­ley pow­er play­er Pe­ter Thiel. Af­ter mak­ing a sprin­kling of plays over the past cou­ple years, Thiel is now putting his weighty name be­hind an­ti­body play­er Al­loy Ther­a­peu­tics as part of a new fundrais­ing round.

Boston-based Al­loy, which was found­ed in 2017, closed a $75 mil­lion Se­ries C on Mon­day, head­lined by Thiel’s in­vest­ment. The biotech is build­ing a hu­man an­ti­body dis­cov­ery plat­form, dubbed ATX-Gx, that us­es high­ly im­muno­com­pe­tent trans­genic mice strains.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.